Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 in Advanced Non-Small Cell Lung Cancer (AURA)
NCT01802632Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Mar 2013; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01802632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802632.